Adenium Biotech ApS

Adenium Biotech focuses on the development and commercialization of novel antibiotics for the treatment of Gram-negative bacterial infections (urinary tract infections and hospital- acquired pneumonia). Complicated urinary tract infections are caused predominantly by bacteria Escherichia coli, which is usually easy to cure, however, hospitals-adapted strains are often multi-resistant and can cause life-threatening infections.

Contact name:

Paul Goldenheim


Ole Maaløes Vej 3, 2200 København N, Denmark

If you can't find it here or have feedback to our website, please do not hesitate to contact or +45 5150 0560

Copyright 2011 Danskbiotek. All rights reserved.